

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (withdrawn and currently amended) A method of treating a ~~human~~ ^{breast} ~~breast~~ tumor in a mammal, wherein said tumor expresses an antigen which specifically binds to the isolated monoclonal antibody ~~or antigen binding fragment thereof~~ produced by ~~[[a clone]]~~ the hybridoma deposited with the ATCC as accession number PTA-4621, or an antigen binding fragment ^{isolated} produced from said monoclonal antibody, comprising administering to said mammal said isolated monoclonal antibody or said antigen binding fragment in an amount effective to reduce said mammal's tumor burden.

Claim 2. (withdrawn and currently amended) The method of claim 1 wherein said isolated monoclonal antibody or antigen binding fragment is conjugated to a cytotoxic moiety.

Claim 3. (withdrawn) The method of claim 2 wherein said cytotoxic moiety is a radioactive isotope.

Claim 4. (withdrawn) The method of claim 1 wherein said isolated monoclonal antibody activates complement.

Claim 5. (withdrawn) The method of claim 1 wherein said isolated monoclonal antibody mediates antibody dependent cellular cytotoxicity.

Claim 6. Cancelled

Claim ⁶7. (withdrawn and currently amended) The method of claim 1 wherein ^{antibody administered} [[said]] ~~the administered monoclonal antibody~~ is a humanized antibody ^{of} ~~produced from the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC under Accession Number PTA-4621~~ or is an antigen binding fragment of said humanized antibody.

Claim ⁷8. (withdrawn and currently amended) The method of claim 1 wherein ^{antibody administered} [[said]] ~~the administered antibody~~ is a ^{of} ~~[[chimerized]] chimeric antibody produced from the isolated monoclonal antibody produced by the hybridoma deposited with the ATCC under Accession Number PTA-4621~~ or is an antigen binding fragment of said chimeric antibody.

Claim ⁸9. (Currently Amended) The isolated monoclonal antibody ~~or antigen binding fragments thereof~~ produced by the

[[clone]] hybridoma deposited with the ATCC [[as]] under
Accession Number PTA-4621, or an antigen binding fragment
produced from said isolated monoclonal antibody.

⁹
of Claim ~~10~~. (Currently Amended) A humanized antibody
~~produced from the~~ [[The]] isolated monoclonal antibody or
~~antigen binding fragments of claim 9, wherein said isolated~~
~~antibody or antigen binding fragments thereof is humanized~~
produced by the hybridoma deposited with the ATCC under
Accession Number PTA-4621, or an antigen binding fragment
produced from said humanized antibody.

¹⁰
Claim ~~11~~. (Currently Amended) The isolated monoclonal
antibody or antigen binding fragments of claim ⁸~~9~~ conjugated with
a member selected from the group consisting of cytotoxic
moieties, enzymes, radioactive compounds, and hematogenous
cells.

¹¹
of Claim ~~12~~. (Currently Amended) A chimeric antibody
~~produced from the~~ [[The]] isolated monoclonal antibody or
~~antigen binding fragments of claim 9, wherein said isolated~~
~~antibody or antigen binding fragments thereof is chimerized~~
produced by the hybridoma deposited with the ATCC under

Accession Number PTA-4621, or an antigen binding fragment produced from said chimeric antibody.

Claim 13. Cancelled

Claim ¹²~~14~~. (Currently Amended) The isolated ~~[[clone]]~~ hybridoma deposited with the ATCC ~~[[as]]~~ under Accession Number PTA-4621.

Claim ¹³~~15~~. (withdrawn and currently amended) A binding assay to determine the presence of cancerous cells in a human tissue sample ~~selected from a human tumor selected from the group consisting of human colon, ovarian, lung, and breast tissue samples comprising:~~

providing ~~[[a]] said human tissue sample from said human tumor;~~

providing the isolated monoclonal antibody ~~or antigen binding fragment thereof~~ produced by the ~~[[clone]]~~ hybridoma deposited with the ATCC ~~[[as]]~~ under Accession Number PTA-4621, or an antigen binding fragment produced from said isolated monoclonal antibody;

contacting said isolated monoclonal antibody or ~~said~~ antigen binding fragment ~~[[thereof]]~~ with said human tissue sample; and

determining binding of said isolated monoclonal antibody or said antigen binding fragment ~~[[thereof]]~~ with said human tissue sample; whereby the presence of said cancerous cells in said human tissue sample is indicated.

Claim 16. Cancelled

Claim 17. (withdrawn and currently amended) A process of isolating or screening for cancerous cells in a human tissue sample selected from ~~a human tumor originating in a tissue selected from the group~~ consisting of human colon, ovarian, lung, and breast tissue comprising:

~~providing a human tissue sample from said human tumor;~~
providing the isolated monoclonal antibody or antigen binding fragment thereof produced by the [[clone]] hybridoma deposited with the ATCC [[as]] under Accession Number PTA-4621 or an antigen binding fragment produced from said monoclonal antibody;

contacting said isolated monoclonal antibody or said antigen binding fragment ~~[[thereof]]~~ with said human tissue sample; and

determining binding of said isolated monoclonal antibody or said antigen binding fragment ~~[[thereof]]~~ with said human tissue sample; whereby

said cancerous cells are isolated by said binding and their presence in said human tissue sample is confirmed.

Claim 18. Cancelled